Welcome & Report

SBAG 8, Washington, DC
Jan 14-16, 2013

Mark V. Sykes
Planetary Science Institute
Recent Activities

- SBAG 7 held June 10-11, 2012 in Pasadena CA
- Co-sponsor (with MEPAG) of Mars Precursor Science Analysis Group (PSAG) to define precursor activities necessary for human missions to Mars (Phobos/Deimos focus by SBAG). Final document completed and delivered to MPPG, Aug 3, 2012.
• SBAG Strategic Knowledge Gap Special Action Team (Rivkin, Lead) submitted report to HEOMD on Nov 28, 2012, identifying SKGs for implementing asteroid mission scenarios and architectures for human exploration. Report distributed to SBAG community for further input. To be an evolving document (discussion this meeting).
• Planetary Science Subcommittee meeting in Washington DC, October 2-3.
• PSS fact-finding telecon, December 21, 2012.
Other Events Since SBAG 7

- **8/20/12.** One mission, InSight (Mars), selected for Discovery.
- **9/24/12.** Congress passes CR until March, 2013 - Administration implements its 21% cut of NASA Planetary.
- **12/5/12.** Mars 2020 Rover announced at AGU.
- **12/5/12.** NRC Report (NASA's Strategic Direction and the Need for a National Consensus) critical of goal of sending humans to an NEA by 2025.
- **1/10/13.** Solar System Exploration Research Virtual Institute Cooperative Agreement Notice release. Includes NEOs and Phobos/Deimos.
Planetary Science Subcommittee Report
• Congress passed 6 month CR, and in the absence of specific direction, the Administration is following the President’s FY13 budget proposal, reducing PSD’s budget from $1.5B to $1.19B.
• NASA will have to pay entire cost of Pu-238 restart.
• Mars Program Planning Group report (promoting MSR) & Europa missions study report (reducing costs).
• PSD building two ASRG flight units, even though not used by Disco selection.
• Senior review of continuing missions discussed.
• Workforce survey presented indicating significant dependence of community on R&A programs.

These meetings can be attended by Webex.
Sparked by PSS questions regarding announcement of Mars 2020 Rover (which seemed to come out of nowhere, inconsistent with decadal recommendations) and indications of continuing decline in R&A selection rates:

![Graph showing trend in PSD Research Proposal Selection Rate (%) as of 1/13/13](chart.png)
SBAG 8 Program

MONDAY

The Future of Human Exploration and Potential Role of NEOs – Different Perspectives & Panel Discussion
– NASA, ESA, DLR, JAXA, CSA

Strategic Knowledge Gaps – Small bodies in support of human exploration – status, presentations, discussion

Planetary Protection/Planetary Defense presentations

Jim Green – Planetary Science Division Update
SBAG 8 Program

TUESDAY

Missions – Results, Status, Planning

Comet ISON

Reports: PDS SBN, ANSMET, ISIS
SBAG 8 Program

WEDNESDAY MORNING

HQ Response to SBAG 7 Findings

Solar System Exploration Research Virtual Institute Status

Detailed report on the status of R&A programs relevant to Small Bodies.

Discussion of Draft Findings from this meeting.

Out before Noon!
NEOO, Discovery, New Frontiers Update

Lindley Johnson, NASA HQ
Backup
Summary of SBAG 7 Findings

Finding 1. The Discovery program has substantially collapsed as a source of planetary missions. In its first decade (1992–2001), ten missions were selected for launch. During its second decade (2002–2011), only one was selected.

First mission of third decade now selected (InSight).

Finding 2. Concern regarding potentially significant resources (to be spent within the agency) to support the B612 private space-based telescope initiative.


Note: SBAG emphasis on the potential game-changing impact of Phobos/Deimos ISRU to human exploration and what needs to be done to determine its actual existence and potential.

Finding 5. Scientists need to be included in the ultimate prioritization of SKGs for human exploration, not just engineers and technologists.

Finding 6. NASA Planetary Science Division investments in missions and research programs should be made on the basis of science alone. Filling SKGs is a reasonable basis for HEOMD investment in PSD or joint activities.